Company news
Antengene Corporation Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
July 28, 2025
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
July 27, 2025
Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025
May 23, 2025
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
May 20, 2025
Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up
March 24, 2025
XPOVIO Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
March 6, 2025
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
March 4, 2025
Antengene Announces XPOVIO Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
February 14, 2025
Decks
- Investor Presentation (November 2022)
Investor deck · 42 slides · November 2022